drugset / Trial / NCT07289542
Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above
Phase 2
Active not recruiting
420 enrolled
Suzhou Abogen Biosciences Co., Ltd.
Abogen Biosciences (Shanghai) Co., Ltd · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The primary objective of this study is to evaluate the immunogenicity and safety of a single injection of two dose levels of ABO1105 in adults aged 50 years or above.
Timeline
- Start
- 2025-09-15
- Primary completion
- 2026-01-07
- Completion
- 2027-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABO1105 | Unknown | — | — |